The Utility of Long-acting Local Anesthetic Agents in Reducing Post-operative Opioid Requirements Following Rhinoplasty

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

June 1, 2020

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2022

Conditions
Pain, PostoperativeLocal Anesthetic
Interventions
DRUG

marcaine bupivacaine

This drug is already FDA approved and used for the indication as a local anesthetic. The study herein would like to examine the pain outcomes of enrolled patients who will either have lidocaine alone OR lidocaine+bupivacaine combination locally prior to rhinoplasty surgery.

DRUG

Lidocaine

This drug is already FDA approved and used for the indication as a local anesthetic. The study herein would like to examine the pain outcomes of enrolled patients who will either have lidocaine alone OR lidocaine+bupivacaine combination locally prior to rhinoplasty surgery.

Trial Locations (1)

70808

Our Lady of the Lake Hospital, Baton Rouge

All Listed Sponsors
collaborator

Louisiana State University Health Sciences Center in New Orleans

OTHER

lead

Our Lady of the Lake Hospital

OTHER

NCT04377204 - The Utility of Long-acting Local Anesthetic Agents in Reducing Post-operative Opioid Requirements Following Rhinoplasty | Biotech Hunter | Biotech Hunter